Disease progression and changes in KL-6 in patients with limited cutaneous systemic sclerosis-associated interstitial lung disease

Respir Investig. 2024 Jan;62(1):44-48. doi: 10.1016/j.resinv.2023.09.003. Epub 2023 Nov 7.

Abstract

Background: Little is known about the annual change in Krebs von Lungen-6 (KL-6) and its correlation with forced vital capacity (FVC) in limited cutaneous systemic sclerosis-associated interstitial lung disease (lcSSc-ILD). We aimed to clarify the correlation during the clinical course.

Methods: We retrospectively reviewed data from consecutive patients with lcSSc-ILD. We measured FVC and KL-6 annually and calculated their annual changes using the difference in absolute values. Decline in FVC was defined as annual decline in FVC ≥5 %.

Results: Thirty-eight patients with SSc-ILD were included. The median age was 62 years and 58 % were female. The median FVC was 87.3 % and the median KL-6 was 1629 U/ml. The median observation period was 55.2 months and the annual changes in FVC and KL-6 were evaluated 151 times simultaneously. The annual change in KL-6 had a significant negative correlation with that in FVC in the first year from the initial evaluation (from the baseline to one-year follow-up) (r = -0.819, p < 0.01), but not after the first year. In the multivariable analysis adjusted by age, sex, and FVC at each year, the annual change of KL-6 (per 100 U/ml) was significantly associated with decline in FVC in the first year (odds ratio: 3.03, 95 % confidence interval: 1.21-7.59, p = 0.02), but not after the first year.

Conclusions: Only in the first year from the initial evaluation, there was negative correlation between the annual change in FVC and that in KL-6 and the annual elevation in KL-6 was associated with decline in FVC in patients with lcSSc-ILD.

Keywords: Disease progression; Interstitial lung disease; Krebs von den Lungen-6; Systemic sclerosis.

MeSH terms

  • Disease Progression
  • Female
  • Humans
  • Lung Diseases, Interstitial* / complications
  • Male
  • Middle Aged
  • Mucin-1
  • Retrospective Studies
  • Scleroderma, Systemic* / complications

Substances

  • Mucin-1